Systematic Literature Review of Clinical, Economic, and Humanistic Outcomes Following Minimally Invasive Glaucoma Surgery or Selective Laser Trabeculoplasty for the Treatment of Open-Angle Glaucoma with or Without Cataract Extraction
Louis Cantor,Dan Lindfield,Federico Ghinelli,Anna W Świder,Francesca Torelli,Carolyn Steeds,Jaime E Dickerson Jr,Dan Q Nguyen
DOI: https://doi.org/10.2147/OPTH.S389406
2023-01-06
Clinical Ophthalmology
Abstract:Louis Cantor, 1 Dan Lindfield, 2 Federico Ghinelli, 3 Anna W &Sacutewider, 3 Francesca Torelli, 3 Carolyn Steeds, 3 Jaime E Dickerson Jr, 4, 5 Dan Q Nguyen 6 1 Eugene and Marilyn Glick Eye Institute, Indiana School of Medicine, Indianapolis, IN, USA; 2 Royal Surrey County Hospital, Guildford, England, UK; 3 Valid Insight, Macclesfield, England, UK; 4 Sight Sciences, Menlo Park, CA, USA; 5 North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX, USA; 6 Mid-Cheshire Hospitals NHS Foundation Trust, Crewe, UK Correspondence: Francesca Torelli, Valid Insight, Ropewalks, Newton St, Macclesfield, SK11 6QJ, UK, Tel +44 203 750 9833 Ext 703, Email Introduction: Selective laser trabeculoplasty (SLT) and minimally invasive glaucoma surgery (MIGS) are increasingly used options for mild-to-moderate open-angle glaucoma (OAG) care. While most MIGS devices are indicated for use in combination with cataract surgery only, with phacoemulsification playing a role in lowering IOP, newer technologies can also be used as standalone glaucoma surgery. Methods: This systematic literature review (SLR) aimed to assess the clinical, economic, and humanistic outcomes of MIGS and SLT for the treatment of OAG and was conducted according to PRISMA guidelines. Studies that assessed MIGS or SLT in at least one treatment arm versus any other glaucoma treatment in adults with mild-to-moderate OAG were included. Clinical, humanistic (health-related quality of life [HRQoL] and patient burden), and economic data were extracted, and the methodological quality of included studies was evaluated. Results: A total of 2720 articles were screened, and 81 publications were included. Fifty-eight reported clinical outcomes. The majority assessed iStent or iStent inject (n=41), followed by OMNI (n=9), gonioscopy-assisted transluminal trabeculotomy (GATT) or the Kahook Dual Blade (KDB) (n=7), Hydrus (n=6), SLT (n=5), Xen Gel Stent (n=2), PreserFlo (n=1), and iTrack (n=1). IOP reduction was observed across prospective studies, varying from − 31% to − 13.7% at month 6 and from − 39% to − 11.4% at year 1 versus baseline. Most adverse events were transient and non-serious. Limited humanistic and economic data were identified. Conclusion: Given their established efficacy and safety, there is a rationale for wider use of MIGS in mild-to-moderate OAG. Of the MIGS devices, iStent and OMNI have the largest clinical evidence base supporting their sustained effectiveness. Keywords: intraocular pressure, IOP, iStent, MIGS, OMNI, SLT Primary open-angle glaucoma (OAG) is a progressive ophthalmic disease that is associated with elevated intraocular pressure (IOP) resulting in damage to the optic nerve causing reduced visual fields and potentially leading to irreversible blindness. 1 Maintaining IOP below 18 mmHg can slow the progression of disease and preserve the visual field in most patients. 2 First-line treatment of OAG usually comprises topical IOP-lowering medications that can delay the onset or reduce the risk of progression of OAG in patients with elevated IOP. 3 However, patient adherence and local adverse effects (AEs) to topical medications can be problematic. 3 If topical IOP-lowering medications are contraindicated (due to their medical history or local or systemic side effects), or if medication does not sufficiently reduce IOP, laser therapy (eg selective laser trabeculoplasty [SLT]) and surgical procedures (conventional surgery or minimally invasive glaucoma surgery [MIGS]) may be used. 3 In the UK, NICE guidelines recommend offering SLT as primary therapy for OAG. 4 SLT lowers IOP by inducing biological changes in the trabecular meshwork (TM), resulting in increased aqueous outflow. 3 In the context of randomized controlled trials, it has been shown that, after 3 years from treatment, 74% of patients randomized to initial SLT remained within target without medication and 95% reached their target IOP, 5 although this might not apply to non-Caucasian patients (eg of African descent) that often present more advanced glaucoma. In terms of surgical interventions, trabeculectomy is historically the most common conventional procedure. Trabeculectomy lowers IOP by creating a fistula between the anterior chamber and the subconjunctival space to provide a lower resistance drainage route for aqueous humor. 3 While it is effective in reducing IOP, trabeculectomy carries a risk of potential complications. 6 Further, antiscarring agents are often applied to the surgical site to decrease the -Abstract Truncated-